Sino Biopharm Secures $2.1B TQC3721 AstraZeneca Agreement
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
DENVER, Colo., June 29, 2026 Palisade Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared...
WESTLAKE VILLAGE, Calif., June 29, 2026 Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
CHICAGO, Ill., June 20, 2026 The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology...
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
